Control Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study
Annals of Otology, Rhinology & Laryngology · 2026-08 · 135 (8) · 591-599
DOI: 10.1177/00034894261434347 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Otology, Rhinology & Laryngology, online erschienen am 02.04.2026. Verfasst von Sevgi Çolak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Türkiye. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Biological Products, Omalizumab. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
This study aimed to determine the prevalence, subtypes, and control status of chronic rhinosinusitis (CRS) among patients with severe asthma receiving biologic therapy in a tertiary allergy clinic.
Methods
A single-center, cross-sectional observational study was conducted in adult patients with severe asthma receiving biologics for at least 6 months. CRS diagnosis and control were assessed based on European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 criteria. The Sinonasal Outcome Test-22 (SNOT-22) was also administered. Statistical analyses were performed using appropriate univariate and multivariate methods.
Results
Among 148 patients with severe asthma receiving biologic therapy, 97 (65.5%) were diagnosed with comorbid CRS. Of these, 68 (45.9%) had CRS with nasal polyps (CRSwNP) and 29 (19.5%) had CRS without nasal polyps (CRSsNP). A total of 54 patients (55.6%) were treated with omalizumab and 43 (44.3%) with mepolizumab. Overall, 32.9% of patients had controlled CRS, 36.0% were partly controlled, and 30.9% were uncontrolled. In multivariable ordinal regression analysis, the presence of N-ERD and higher BMI were associated with poorer CRS control, whereas early-onset asthma and prior maintenance systemic corticosteroid use were associated with better control, suggesting that these factors may be related to CRS control status in this population.
Conclusions
CRS is highly prevalent among patients with severe asthma receiving biologics, and approximately one-third remain uncontrolled despite treatment. These findings emphasize the importance of regular upper airway assessment and may inform future strategies for optimizing biologic selection and treatment outcomes in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Türkiye.
- Division of Immunology and Allergy, Department of Internal Medicine, Ankara University School of Medicine, Türkiye.
- Department of Otorhinolaryngology, Ankara Bilkent City Hospital, Türkiye.
ORCID-Profile: Sevgi Çolak, Ömür Aydin, Mustafa Çolak, Sevim Bavbek, Betül Ayşe Sin, Dilşad Mungan
Zitieren
APA
Çolak, S., Çelebi Sözener, Z., Aydin, Ö., Çolak, M., Bavbek, S., Sin, B. A., Demirel, Y. S., & Mungan, D. (2026). Control Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study. Annals of Otology, Rhinology & Laryngology, 135(8), 591-599. https://doi.org/10.1177/00034894261434347
Vancouver
Çolak S, Çelebi Sözener Z, Aydin Ö, Çolak M, Bavbek S, Sin BA, et al. Control Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study. Annals of Otology, Rhinology & Laryngology. 2026;135(8):591-599. doi:10.1177/00034894261434347
BibTeX
@article{olak2026,
author = {Çolak, Sevgi and Çelebi Sözener, Zeynep and Aydin, Ömür and Çolak, Mustafa and Bavbek, Sevim and Sin, Betül Ayşe and Demirel, Yavuz Selim and Mungan, Dilşad},
title = {Control Status of Chronic Rhinosinusitis in Severe Asthma Patients Receiving Biologics: A Real-World Cross-Sectional Study},
journal = {Annals of Otology, Rhinology & Laryngology},
year = {2026},
volume = {135},
number = {8},
pages = {591--599},
doi = {10.1177/00034894261434347}
}
EUVIMED